Key result
Cardiac biomarkers show promise for diagnosing myocardial injury in perinatal asphyxia, but need established reference values.
Why the study?
Perinatal hypoxia causes multi-organ injury including the heart, but no cutoff values for cardiac biomarkers in newborns have been established for routine use.
What is the diagnostic utility of cardiac biomarkers in newborns with perinatal asphyxia?
What is the diagnostic utility of cardiac biomarkers in newborns with perinatal asphyxia?
Cardiac biomarkers are increasingly used in neonatal diagnostics, but established cutoff values for newborns with perinatal asphyxia are currently lacking.
Answers are grounded in this paper and cite their sources.
Cautious biomarker interpretation is warranted in asphyxiated neonates; leaves open validation of diagnostic thresholds.
Perinatal hypoxia is one of the more common complications of the early adaptation period. This condition is defined as a disorder of tissue oxygenation during labour and is responsible for approximately 23% of neonatal mortality. Perinatal hypoxia can cause injury and failure of many organs, including the brain, heart and kidneys, mainly in the mechanism of the ischaemic-reperfusion injury. Currently, biochemical markers are more frequently incorporated in neonatal diagnostics. Routinely used in adult patients, these organ-specific chemicals enable diagnosis with high sensitivity and specificity. The manuscript presents a review of research on the use of cardiac markers (N-terminal fragment of pro-B-type natriuretic peptide, cardiac troponins I and T, and cardiac creatine kinase isoenzyme) in selected neonatal diseases. Still, no cutoff values have been established for any of the markers described in this paper. Therefore, for routine use of cardiac markers in the neonatal population, further studies are needed to determine the range of cutoff values and factors that may cause their fluctuation.
No takes yet. Share an insight, caveat, or question.
Wojnarowicz et al. (2022) conducted a review in Perinatal asphyxia. Cardiac biomarkers (NT-proBNP, cardiac troponins, CK-MB) was evaluated. Cardiac biomarkers such as NT-proBNP, cardiac troponins, and CK-MB show promise in diagnosing myocardial injury in newborns with perinatal asphyxia, though routine use requires establishing specific reference values.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: